Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively

Oncology Letters

Volumn 5, Issue 5, 2013, Pages 1527-1535

  Campos, Marcelo ^a   De Campos, Silvana Gisele Pegorin ^a   Ribeiro, Guilherme Gomes ^a   Eguchi, Flávia Coltri ^a   Da Silva, Sandra Regina Morini ^a   De Oliveira, Cleyton Zanardo ^a   Da Costa, Allini Mafra ^a   Curcelli, Emílio Carlos ^b   Nunes, Marcos Ceita ^a   Penna, Valter ^a   Longatto Filho, Adhemar ^a,c,d  

^a Pio XII Foundation   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF MINHO   (Portugal)

Author keywords

CD100; Ki 67; Poor prognosis; Recurrence; Soft tissue sarcomas

Indexed keywords

CD 100; KI 67 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

AMPUTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHICS; ETHNICITY; FEMALE; FIBROSARCOMA; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RISK FACTOR; SOFT TISSUE SARCOMA;

EID: 84875711548     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1226     Document Type: Article

References (31)

1. Fletcher CDM, Sundaram M, Rydholm A, Coindre JM and SingerS: Soft tissue tumours: Epidemiology, clinical features, histopathological typing and grading. In: World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK and Mertens F (eds). IARC Press, Lyon, pp12-18, 2002.
2. Jones NB, Iwenofu H, Scharschmidt T and Kraybill W: Prognostic factors and staging for soft tissue sarcomas: an update. Surg Oncol Clin N Am 21: 187-200, 2012.
3. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11: 541-557, 2011.
4. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A and Apice G: Biological prognostic factors in adult soft tissue sarcomas. Anticancer Res 25: 4519-4526, 2005.
5. Endl E and Gerdes J: The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257: 231-237, 2000.
6. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
7. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, DiComo CJ, Brennan MF and Cordon-Cardo C: High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92: 869-874, 2001.
8. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM and BrennanMF: Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 83: 490-497, 1998.
9. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, DorfmanDM, Cardoso AA, Bensussan A, Nadler LM and Freeman GJ: Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci USA 93: 11780-11785, 1996.
10. Goodman CS, Kolodkin AL, Luo Y, Püschel AW and Raper JA: Unified nomenclature for the semaphorins/collapsins. Cell 97: 551-552, 1999.
11. Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H, Iwahori K, Uchida J, Yasui T, Matsumoto M, YoshidaK, Yakura H, Pan C, Parnes JR and Kikutani H: Identification of CD72 as a lymphocyte receptor for the class IV semaphoring CD100: a novel mechanism for regulating B cell signaling. Immunity 13: 621-631, 2000.
12. Tessier-Lavigne M and Goodman SC: The molecular biology of axon guidance. Science 274: 1123-1133, 1996.
13. Luo Y, Raible D and Raper JA: Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75: 217-227, 1993.
14. Kolodkin AL, Matthes DJ and Goodman CS: The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75: 1389-1399, 1993.
15. Behar O, Golden JA, Mashimo H, Schoen FJ and Fishman MC: Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383: 525-528, 1996.
16. Kitsukawa T, Shimono A, Kawakami A, Kondoh H and FujisawaH: Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121: 4309-4318, 1995.
17. Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, Swanton M, Waggoner B, Fishel R, Franklin W, Gemmill R and Drabkin H: Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene 12: 1289-1297, 1996.
18. Sekido Y, Bader S, Latif F, Chen JY, Duh FM, Wei MH, et al: Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc Natl Acad Sci USA 93: 4120-4125, 1996.
19. Mizui M, Kumanogoh A and Kikutani H: Immune semaphorins: novel features of neural guidance molecules. J Clin Immunol 29: 1-11, 2009.
20. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, Bussolino F and Giordano S: Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105: 4321-4329, 2005.
21. Conrotto P, Corso S, Gamberini S, Comoglio PM and GiordanoS: Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 5131-5137, 2004.
22. Ch'ng E, Tomita Y, Zhang B, He J, Hoshida Y, Qiu Y, Morii E, Nakamichi I, Hamada K, Ueda T and Aozasa K: Prognostic significance of CD100 expression in soft tissue sarcoma. Cancer 110: 164-172, 2007.
23. Ch'ng ES and Kumanogoh A: Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 9: 251, 2010.
24. Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, GoshimaY, Morita S, Endo I, Maeda S, Nakajima A and Nakagama H: Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci 102: 2029-2037, 2011.
25. Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhäberle E, Metzler D, Ahr A, Solbach C, Karn T and Kaufmann M: Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13: 1115-1122, 2007.
26. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.
27. Choong PF, Akerman M, Willén H, Andersson C, Gustafson P, Baldetorp B, Fernö M, Alvegård T and Rydholm A: Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation-a marker of metastasis? APMIS 102: 915-924, 1994.
28. Ueda T, Aozasa K, Tsujimoto M, Ohsawa M, Uchida A, AokiY, Ono K and Matsumoto K: Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 63: 1607-1611, 1989.
29. Jensen V, Sørensen FB, Bentzen SM, Ladekarl M, Nielsen OS, Keller J and Jensen OM: Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 32: 536-546, 1998.
30. Huutanen RL, Blomqvist CP, Wiklund TA, Böhling TO, Virolainen MJ, Tukiainen EJ, Tribukait B and Andresson LC: Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer 79: 945-951, 1999.
31. Popiolek D, Yee H, Levine P, Vamvakas E and DemopoulosRI: MIB1 as a possible predictor of recurrence in low-grade endometrial stromal sarcoma of the uterus. Gynecol Oncol 90: 353-357, 2003.